What is Alnylam Pharmaceuticals's vutrisiran — interest expense?

Alnylam Pharmaceuticals (ALNY) reported vutrisiran — interest expense of $23.93M in Q1 2026.

How has Alnylam Pharmaceuticals's vutrisiran — interest expense changed year-over-year?

Alnylam Pharmaceuticals's vutrisiran — interest expense increased by 17.1% year-over-year, from $20.43M to $23.93M.

Vutrisiran — Interest Expense

Alnylam Pharmaceuticals Vutrisiran — Interest Expense increased by 17.1% to $23.93M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 17.1%, from $20.43M to $23.93M.

Analysis

StatementSegment

First reportedQ1 2025

Last reportedQ1 2026

Metric ID: alny_segment_vutrisiran_interest_expense

Historical Data

5 periods

	Q1 '25	Q2 '25	Q3 '25	Q4 '25	Q1 '26
Value	$20.43M	$20.43M	$20.43M	$20.43M	$23.93M
QoQ Change	—	+0.0%	+0.0%	+0.0%	+17.1%
YoY Change	—	—	—	—	+17.1%

Range$20.43M – $23.93M

CAGR+17.1%

Avg YoY Growth+17.1%

Median YoY Growth+17.1%

Current Streak4+ quarters growth

Frequently Asked Questions

What is Alnylam Pharmaceuticals's vutrisiran — interest expense?: Alnylam Pharmaceuticals (ALNY) reported vutrisiran — interest expense of $23.93M in Q1 2026.
How has Alnylam Pharmaceuticals's vutrisiran — interest expense changed year-over-year?: Alnylam Pharmaceuticals's vutrisiran — interest expense increased by 17.1% year-over-year, from $20.43M to $23.93M.